Related references
Note: Only part of the references are listed.
Article
Biochemistry & Molecular Biology
Wanwisa Dejnirattisai et al.
Summary: On November 24, 2021, the sequence of a new SARS-CoV-2 variant, Omicron-B.1.1.529, was announced. Compared to previous variants, Omicron has a higher number of mutations in the Spike (S) protein. Serum neutralization of Omicron by individuals vaccinated or previously infected with Alpha, Beta, Gamma, or Delta variants is significantly reduced or ineffective. Third vaccine doses can boost neutralization titers against Omicron, and high titers are observed in both vaccinated individuals and those infected with the Delta variant. Most potent monoclonal antibodies and antibodies under development are unable to effectively neutralize Omicron due to mutations in its Spike protein. Omicron has structural changes compared to earlier viruses and utilizes mutations that enhance its binding to ACE2, allowing for immune escape. This results in a large number of mutations in the ACE2 binding site and a rebalancing of receptor affinity similar to earlier pandemic viruses.
Article
Biochemistry & Molecular Biology
Pengcheng Han et al.
Summary: The study found that the omicron variant, unlike other variants, has a similar affinity to the human receptor ACE2 as the prototype variant. Multiple mutations in the omicron variant may compensate for both immune escape and transmissibility. The complex structures of the omicron and delta variants binding to ACE2 provide insights into how specific mutations affect the binding.
Article
Biochemistry & Molecular Biology
Markus Hoffmann et al.
Summary: The Omicron variant of SARS-CoV-2 is spreading rapidly and shows resistance to most therapeutic antibodies. It also evades neutralization by antibodies induced by infection or vaccination more efficiently than the Delta variant. This suggests that therapeutic antibodies may not be effective against the Omicron variant, and double vaccination with BNT162b2 may not provide adequate protection against severe disease caused by this variant.
Letter
Immunology
Jie Hu et al.
CELLULAR & MOLECULAR IMMUNOLOGY
(2022)
Article
Immunology
Vivek Naranbhai et al.
Summary: Understanding the immunogenicity and effectiveness of SARS-CoV-2 vaccines is crucial. This study compared the immunogenicity and effectiveness of mRNA-1273, BNT-162b2, and Ad26.COV2.S in healthy adults. The results showed that mRNA vaccines and convalescent individuals had comparable antibody and neutralization titers, while Ad26.COV2.S had lower antibody concentrations. mRNA1273 and BNT162b2 induced higher T-cell responses. Prior infection was associated with high antibody concentrations and neutralization even after a single dose. Meta-analysis showed differences in effectiveness against infection, hospitalization, and death, with mRNA1273 being the most effective.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Letter
Medicine, General & Internal
Wanwisa Dejnirattisai et al.
Article
Multidisciplinary Sciences
Delphine Planas et al.
Summary: The Omicron variant of SARS-CoV-2, identified in November 2021, has spread rapidly worldwide and shows resistance to most therapeutic monoclonal antibodies and vaccine-elicited antibodies. However, it can be neutralized by antibodies generated by a booster vaccine dose.
Article
Multidisciplinary Sciences
Juan Manuel Carreno et al.
Summary: The Omicron variant of SARS-CoV-2, first identified in South Africa and Botswana in November 2021, has rapidly spread globally with high transmissibility. It has an unprecedented number of mutations in its spike gene, leading to immune escape and reduced vaccine efficacy. The neutralizing and binding activity against Omicron varies among individuals with different vaccination and infection histories.
Article
Multidisciplinary Sciences
Elisabetta Cameroni et al.
Summary: The Omicron variant of SARS-CoV-2 has raised concerns due to its 37 amino acid substitutions in the spike protein, particularly in the receptor-binding domain (RBD), leading to increased binding affinity with human ACE2. Neutralizing activity against Omicron was greatly reduced in convalescent and vaccinated individuals compared to the ancestral virus, but this decrease was less significant after a third vaccine dose. Broadly neutralizing monoclonal antibodies recognizing conserved RBD epitopes may be crucial in combating the Omicron variant and future zoonotic transmissions.
Article
Multidisciplinary Sciences
Sandile Cele et al.
Summary: The study found that the Omicron variant has reduced neutralizing effectiveness in individuals vaccinated with Pfizer BNT162b2, but those who had previously been infected with SARS-CoV-2 showed better neutralization against Omicron.
Article
Multidisciplinary Sciences
Yunlong Cao et al.
Summary: The Omicron variant of SARS-CoV-2 contains 15 mutations in the receptor-binding domain, leading to evasion of over 85% of tested neutralizing antibodies. Different epitope groups of neutralizing antibodies are affected to varying degrees by single mutations of Omicron. Antibodies targeting the conserved region of sarbecovirus remain most effective against Omicron.
Article
Multidisciplinary Sciences
Lihong Liu et al.
Summary: The B.1.1.529/Omicron variant of SARS-CoV-2, initially detected in southern Africa, has rapidly spread globally and is expected to become dominant due to its enhanced transmissibility in the coming weeks. This variant poses a threat to the efficacy of current COVID-19 vaccines and antibody therapies due to its significant antibody resistance. Even individuals who have received vaccines and booster doses may have reduced neutralizing activity against B.1.1.529.
Article
Multidisciplinary Sciences
Matthew McCallum et al.
Summary: The SARS-CoV-2 Omicron variant evades antibody-mediated immunity and exhibits enhanced affinity for host cells due to accumulation of spike mutations and remodeling of interactions with the ACE2 receptor.
Article
Multidisciplinary Sciences
Lei Peng et al.
Summary: This study reports the development of monoclonal antibodies (mAbs) that effectively neutralize SARS-CoV-2 variants of concern. By using high-throughput single cell sequencing, the researchers identified two highly potent mAb clones with strong neutralizing activity against SARS-CoV-2 and its emerging variants. Cryo-EM structures revealed the distinct epitopes, binding patterns, and conformations of these neutralizing antibodies. The lead clones also showed potent efficacy in vivo against authentic SARS-CoV-2 in both preventive and therapeutic settings. Furthermore, a humanized antibody was generated and showed strong potency against both the original virus and the B.1.617.2 Delta variant. These mAbs expand the repertoire of therapeutics against SARS-CoV-2 and emerging variants.
NATURE COMMUNICATIONS
(2022)
Article
Multidisciplinary Sciences
Zhenhao Fang et al.
Summary: Researchers have developed an Omicron-specific mRNA vaccine candidate and tested its efficacy in animals. The vaccine shows strong antibody response and acts as a booster to improve the effectiveness of the existing vaccine. Interestingly, the heterologous Omicron booster demonstrates higher neutralization potency against the Omicron variant compared to the homologous booster, with comparable effectiveness against the Delta variant.
NATURE COMMUNICATIONS
(2022)
Article
Medicine, General & Internal
Sham Mailankody et al.
Summary: The study demonstrates that GPRC5D is an active immunotherapeutic target in multiple myeloma, and GPRC5D-targeted CAR T-cell therapy shows promising efficacy in heavily pretreated patients, including those who relapsed after BCMA CAR T-cell therapy.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Virology
Yudi Zhang et al.
JOURNAL OF VIROLOGY
(2021)
News Item
Biotechnology & Applied Microbiology
Asher Mullard
Summary: After 35 years since the FDA approved the first monoclonal antibody, these biologics now make up nearly one fifth of the agency's new drug approvals each year.
NATURE REVIEWS DRUG DISCOVERY
(2021)
Letter
Oncology
Yue Tan et al.
BLOOD CANCER JOURNAL
(2021)
Review
Biochemistry & Molecular Biology
Dehua Yang et al.
Summary: Recent progress in understanding the structure-function relationships of G protein-coupled receptors has accelerated drug development significantly. This article aims to provide a comprehensive overview of this important field to a broader readership interested in drug discovery.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2021)
Article
Cell Biology
Eric L. Smith et al.
SCIENCE TRANSLATIONAL MEDICINE
(2019)
News Item
Biotechnology & Applied Microbiology
Elie Dolgin
NATURE REVIEWS DRUG DISCOVERY
(2018)
Review
Biochemistry & Molecular Biology
Xianjun Zhang et al.
TRENDS IN BIOCHEMICAL SCIENCES
(2018)
Review
Pharmacology & Pharmacy
Martial Ruat et al.
TRENDS IN PHARMACOLOGICAL SCIENCES
(2014)
Review
Immunology
Thomas Doerner et al.
INTERNATIONAL REVIEWS OF IMMUNOLOGY
(2012)
Review
Medicine, Research & Experimental
Catherine J. Hutchings et al.
Article
Multidisciplinary Sciences
Beili Wu et al.
Article
Medicine, Research & Experimental
Xiaodong Xiao et al.
